Core Viewpoint - The stock of Kefu Medical (301087) has shown a positive performance with a closing price of 50.78 yuan, reflecting a 2.32% increase as of January 6, 2026, with significant trading activity and a notable net inflow of funds [1][2]. Financial Performance - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, representing a year-on-year increase of 6.63% [2]. - The net profit attributable to shareholders reached 260 million yuan, up by 3.3% year-on-year, while the net profit excluding non-recurring items was 222 million yuan, reflecting a 1.46% increase [2]. - In Q3 2025, the company achieved a quarterly main revenue of 902 million yuan, marking a significant year-on-year growth of 30.72% [2]. - The quarterly net profit attributable to shareholders was approximately 92.83 million yuan, which is a 38.68% increase compared to the same quarter last year [2]. - The quarterly net profit excluding non-recurring items was about 85.80 million yuan, showing a substantial increase of 62.68% year-on-year [2]. - The company's debt ratio stands at 27.37%, with investment income of 18.18 million yuan and financial expenses of -3.77 million yuan, while the gross profit margin is reported at 53.35% [2]. Market Activity - On January 6, 2026, the stock experienced a trading volume of 133,700 hands and a total transaction value of 663 million yuan [1]. - The net inflow of main funds was 48.61 million yuan, accounting for 7.33% of the total transaction value, while retail investors saw a net outflow of 47.12 million yuan, representing 7.1% of the total [1][2]. - Over the past 90 days, 8 institutions have provided ratings for the stock, with 7 buy ratings and 1 hold rating, and the average target price set by institutions is 54.56 yuan [2].
股票行情快报：可孚医疗（301087）1月6日主力资金净买入4860.52万元